SLCTR/2018/035招募中2 期
Pharmacotherapeutic and physicochemical evaluation of Ayabirungarajakarpam – A poly herbometallic drug for Paandu –Anaemia
Dr. V. Elango0 个研究点目标入组 216 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 216
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age – 19 -60 years
- •Male and female
- •With the following cardinal signs of iron deficiency anaemia
- •2. Palpitation
- •3. Extreame fatigue
- •4. Exertional dyspnoea
- •With a hemoglobin value of 7 – 11g/dL
- •With a serum ferritin level of<12 micrograms/L
排除标准
- •Patients with
- •- Haemoglobin below7g/dL
- •- Serum ferritin below 8 micrograms/L
- •- Diagnosed with any other type of anaemia other than Iron deficiency anaemia.
- •Patients with the following complications
- •-Cardiac diseases
- •-Renal diseases
- •-Liver diseases
- •-Diabetes mellitus
- •-Hypertension
- •-Thalassaemia minor
- •-Bleeding disorders
- •-Haemoglopinapathies
- •-Defective absorption E.g. Patients with gastrectomy and gastrojejunostomy.
- •Lactating mothers
研究者
相似试验
已完成
不适用
A study to investigate the effect of Nagapheni (Optunia elatior Mill.) in the treatment of anemia.CTRI/2015/02/005547Institute for post gradute teaching and research in Ayurevda gujarat ayurveda university jamnagar60
尚未招募
不适用
A study on the pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanilKCT0007066Inje University Busan Paik Hospital15
进行中（未招募）
不适用
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-EEInstitut de Recherches Internationales Servier125
进行中（未招募）
不适用
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-HUInstitut de Recherches Internationales Servier200
进行中（未招募）
不适用
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).Patients with chronic heart failure and left ventricular systolicdysfunctionMedDRA version: 17.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2013-003000-39-BEInstitut de Recherches Internationales Servier125